

HMRI partners with Novartis Australia to supercharge heart health

19 February 2025 | News

To prioritise lipid management and cardiovascular disease, integrating digital tools and patient education to improve outcomes



The Hunter Medical Research Institute (HMRI) has announced a new partnership with Novartis Australia, formalised through a Memorandum of Understanding (MoU), supported by collaboration with the University of Newcastle.

This agreement sets the foundation for future collaboration between HMRI and Novartis, allowing both organisations to work closely to discuss and plan potential research projects that will have a significant impact on healthcare outcomes.

The MoU represents a strategic commitment to fostering innovative medical research, leveraging HMRI and University of Newcastle expertise in world-class research and Novartis' leadership in pioneering medical solutions.

By working together, both organisations will explore opportunities to develop projects that align with their shared vision of advancing medical science and improving patient care.

A key feature of this agreement is the establishment of a steering committee, tasked with responsibility for identifying and prioritising research initiatives under the partnership. This committee will play a crucial role in deciding which projects should be pursued, how they should be structured, and what steps need to be taken to bring them to fruition.

The steering committee will consist of experts from Hunter Medical Research Institute and Novartis; ensuring that each project is scientifically rigorous, strategically aligned, and practically achievable. This structure provides a clear framework for decision-making and ensures that all projects undertaken under the MoU are well-positioned to deliver real-world impact.

Image caption- (L) Todd Williams, Chief of Research Partnerships, HMRI, and (R) Matt Zeller, Country President, Novartis Australia and New Zealand